Payment overview · 2025
General Payments
$459.09
25 reported records · 8 companies
Healthcare provider profile · identity verified
Sunit B Desai, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · UNION BEACH, NJ · NPI 1861496457
Verified facts
What the public records show
CMS Open Payments records show Sunit B Desai, M.D. received $459.09 in general payments during 2025 across 25 reported records.
AstraZeneca Pharmaceuticals LP accounted for 32.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Ozempic, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Lokelma by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Jardiance by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Ozempic by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Lantus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $147.28 | 32.1% | 8 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $131.53 | 28.6% | 6 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $67.05 | 14.6% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $50.89 | 11.1% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $17.68 | 3.9% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $15.84 | 3.5% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $14.83 | 3.2% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $13.99 | 3.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $459.09 | 25 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $131.53 | 6 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $69.15 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $61.34 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $50.89 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $45.17 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $31.75 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $31.75 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $17.68 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $15.84 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $14.83 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $13.99 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 39 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 40 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 47 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
12 | 12 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
47 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
34 | 11 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
40 | 14 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 471 | 117 |
| Atorvastatin Calcium | Atorvastatin Calcium | 442 | 117 |
| Eliquis | Apixaban | 420 | 55 |
| Levothyroxine Sodium | Levothyroxine Sodium | 355 | 78 |
| Metformin Hcl | Metformin Hcl | 288 | 69 |
| Furosemide | Furosemide | 248 | 56 |
| Metoprolol Succinate | Metoprolol Succinate | 241 | 65 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 238 | 73 |
| Gabapentin | Gabapentin | 200 | 47 |
| Pantoprazole Sodium | Pantoprazole Sodium | 196 | 54 |
| Alprazolam | Alprazolam | 169 | 47 |
| Sertraline Hcl | Sertraline Hcl | 169 | 19 |
| Losartan Potassium | Losartan Potassium | 164 | 53 |
| Simvastatin | Simvastatin | 156 | 35 |
| Metoprolol Tartrate | Metoprolol Tartrate | 155 | 41 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 151 | 45 |
| Tamsulosin Hcl | Tamsulosin Hcl | 142 | 36 |
| Potassium Chloride | Potassium Chloride | 124 | 24 |
| Lisinopril | Lisinopril | 113 | 30 |
| Carvedilol | Carvedilol | 109 | 28 |
| Clopidogrel | Clopidogrel Bisulfate | 104 | 26 |
| Escitalopram Oxalate | Escitalopram Oxalate | 104 | 18 |
| Trazodone Hcl | Trazodone Hcl | 94 | 16 |
| Levetiracetam | Levetiracetam | 90 | 12 |
| Januvia | Sitagliptin Phosphate | 81 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 80 | 16 |
| Divalproex Sodium | Divalproex Sodium | 78 | 11 |
| Tramadol Hcl | Tramadol Hcl | 73 | 27 |
| Montelukast Sodium | Montelukast Sodium | 70 | 20 |
| Quetiapine Fumarate | Quetiapine Fumarate | 69 | 14 |
| Enoxaparin Sodium | Enoxaparin Sodium | 66 | suppressed |
| Lactulose | Lactulose | 64 | suppressed |
| Mirtazapine | Mirtazapine | 63 | 14 |
| Allopurinol | Allopurinol | 60 | 17 |
| Donepezil Hcl | Donepezil Hcl | 58 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 56 | 12 |
| Azithromycin | Azithromycin | 54 | 47 |
| Xarelto | Rivaroxaban | 54 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 53 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 53 | 13 |
| Hydrochlorothiazide | Hydrochlorothiazide | 52 | 16 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 52 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 51 | suppressed |
| Latanoprost | Latanoprost | 50 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 49 | suppressed |
| Clonazepam | Clonazepam | 48 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 47 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 47 | 12 |
| Olanzapine | Olanzapine | 46 | suppressed |
| Famotidine | Famotidine | 43 | 18 |
| Prednisone | Prednisone | 43 | 14 |
| Memantine Hcl | Memantine Hcl | 42 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 41 | suppressed |
| Ozempic | Semaglutide | 40 | 14 |
| Risperidone | Risperidone | 40 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 39 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 38 | 32 |
| Insulin Lispro | Insulin Lispro | 38 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 37 | suppressed |
| Valsartan | Valsartan | 37 | 11 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 36 | 14 |
| Glipizide | Glipizide | 36 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 35 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 34 | suppressed |
| Jardiance | Empagliflozin | 34 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 34 | suppressed |
| Methylprednisolone | Methylprednisolone | 33 | 25 |
| Omeprazole | Omeprazole | 33 | 16 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 32 | 26 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 32 | 18 |
| Paroxetine Hcl | Paroxetine Hcl | 32 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 31 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 30 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 29 | 13 |
| Chlorthalidone | Chlorthalidone | 28 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 28 | suppressed |
| Spironolactone | Spironolactone | 28 | suppressed |
| Entresto | Sacubitril/Valsartan | 27 | suppressed |
| Nystatin | Nystatin | 27 | 13 |
| Sevelamer Carbonate | Sevelamer Carbonate | 27 | suppressed |
| Synthroid | Levothyroxine Sodium | 27 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 26 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 26 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 25 | suppressed |
| Aptiom | Eslicarbazepine Acetate | 25 | suppressed |
| Ramipril | Ramipril | 25 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 24 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 23 | suppressed |
| Glimepiride | Glimepiride | 23 | suppressed |
| Irbesartan | Irbesartan | 23 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 22 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 21 | suppressed |
| Finasteride | Finasteride | 21 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 21 | 15 |
| Nifedipine Er | Nifedipine | 21 | suppressed |
| Topiramate | Topiramate | 21 | suppressed |
| Diazepam | Diazepam | 20 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 20 | suppressed |
| Piperacillin-Tazobactam | Piperacillin Sodium/Tazobactam | 20 | suppressed |
| Pradaxa | Dabigatran Etexilate Mesylate | 20 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 20 | suppressed |
| Atenolol | Atenolol | 19 | suppressed |
| Bumetanide | Bumetanide | 19 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 19 | suppressed |
| Meloxicam | Meloxicam | 19 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 18 | 17 |
| Methenamine Hippurate | Methenamine Hippurate | 18 | suppressed |
| Ranolazine Er | Ranolazine | 18 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 18 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Nystop | Nystatin | 17 | suppressed |
| Pregabalin | Pregabalin | 17 | suppressed |
| Baclofen | Baclofen | 16 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 16 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 16 | suppressed |
| Dropsafe Pen Needle | Pen Needle, Diabetic, Safety | 16 | suppressed |
| Fentanyl | Fentanyl | 16 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 16 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 16 | suppressed |
| Levofloxacin | Levofloxacin | 16 | suppressed |
| Lorazepam | Lorazepam | 16 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 15 | suppressed |
| Celecoxib | Celecoxib | 15 | suppressed |
| Cephalexin | Cephalexin | 15 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 15 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 15 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 15 | 14 |
| Oxycodone Hcl | Oxycodone Hcl | 15 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 15 | suppressed |
| Acetazolamide | Acetazolamide | 14 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 14 | suppressed |
| Methotrexate | Methotrexate Sodium | 14 | suppressed |
| Naproxen | Naproxen | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | 12 |
| Santyl | Collagenase Clostridium Hist. | 14 | suppressed |
| Telmisartan | Telmisartan | 14 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 14 | suppressed |
| Bupropion Xl | Bupropion Hcl | 13 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 13 | 11 |
| Nitroglycerin Patch | Nitroglycerin | 13 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 12 | 12 |
| Diclofenac Sodium Er | Diclofenac Sodium | 12 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 12 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 11 | suppressed |
| Briviact | Brivaracetam | 11 | suppressed |
| Cyclosporine | Cyclosporine | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 11 | suppressed |
| Rinvoq | Upadacitinib | 11 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $459.09 · 25 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, Cologuard Collection Kit, FARXIGA, LEQVIO, MOUNJARO, Ozempic, Rybelsus, TRELEGY ELLIPTA, TZIELD, ZORYVE | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error